Navigation Links
Perrigo Reports Record Quarterly Revenue and Adjusted Earnings and Raises Full Year Adjusted EPS Guidance
Date:10/27/2011

ntsAs AdjustedGAAPAs AdjustedNet sales

$   725,295$
-$   725,295$   641,322$
-$   641,32213%13%Cost of sales

497,71642,362

(a,b)

455,354427,3687,174

(a)

420,19416%8%Gross profit

227,57942,362269,941213,9547,174221,1286%22%Operating expensesDistribution

10,264-10,2648,333-8,33323%23%Research and development

19,638(3,500)

(c)

23,13817,727-17,72711%31%Selling and administration

96,12513,620

(a,d)

82,50576,1274,113

(a)

72,01426%15%Total

126,02710,120115,907102,1874,11398,074Operating income

101,55252,482154,034111,76711,287123,054-9%25%Interest, net

12,570-12,57010,087-10,08725%25%Other expense (income), net

229-229(559)-(559)--Income from continuing operations before income taxes

88,75352,482141,235102,23911,287113,526-13%24%Income tax expense

18,29519,620

(e)

37,91528,5613,615

(e)

32,176-36%18%Income from continuing operations

$
70,458$
32,862$   103,320$
73,678$
7,672$
81,350-4%27%Diluted earnings per share from continuing operations

$
.75$
.10$
.79$
.87-5%26%Diluted weighted average shares outstanding

93,95393,95393,26993,269Selected ratios as a percentage of net sales   Gross profit

31.4%37.2%33.4%34.5%   Operating expenses

17.4%16.0%15.9%15.3%   Operating income

14.0%21.2%17.4%19.2%(a) Deal-related amortization(b) Inventory step-up of $27,179(c) Proceeds from sale of pipeline research and development projects(d) Acquisition-related costs of $8,782(e) Total tax effect for non-GAAP pre-tax adjustmentsTable IIPERRIGO COMPANYREPORTABLE SEGMENTSRECONCILIATION OF NON-GAAP MEASURES(in thousands)(unaudited)Three Months EndedConsumer HealthcareSeptember 24, 2011September 25, 2010% ChangeGAAPNon-GAAP AdjustmentsAs AdjustedGAAPNon-GAAP AdjustmentsAs AdjustedGAAPAs AdjustedNet sales'/>"/>

SOURCE Perrigo Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Perrigo Announces Approval for Over-the-Counter Childrens Cetirizine Oral Solution
2. Perrigo and Partner Cobrek Confirms Filing for Generic Version of Evoclin(R) and Announcement of Lawsuit by Stiefel
3. Perrigo Announces FDA Final Approval for Polyethylene Glycol 3350
4. Perrigo Confirms Filing for Generic Version of Mens Rogaine(R) Foam
5. Perrigo Company Will Release First Quarter Fiscal 2010 Results on November 2, 2009
6. Perrigo Company Announces Dividend Increase
7. Perrigo Company Announces Quarterly Dividend
8. Perrigo Company Will Release Second Quarter Fiscal 2010 Results on February 2, 2010
9. Perrigo Company to Present at the 28th Annual J.P. Morgan Healthcare Conference
10. Perrigo Company To Present at the Sidoti Emerging Growth Conference
11. Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... BOULDER, Colo. , Nov. 25, 2014 ... ARRY ) today announced that its Chief ... speak at the following upcoming conferences.  The ... conferences through webcasts on the Array BioPharma ... ConferenceDate:Wednesday, December 3, 2014Time:1:30 p.m.  Eastern Time ...
(Date:11/26/2014)... 25, 2014 Halozyme Therapeutics, Inc. (NASDAQ: ... Conference in New York on Wednesday, ... Dr. Helen Torley , President and Chief Executive ... will be webcast through the "Investors" section of Halozyme,s corporate ... made available for 90 days following the event. To access ...
(Date:11/24/2014)... Juno Therapeutics today announced that the ... company,s JCAR015 chimeric antigen receptor product candidate.  The ... refractory B-cell acute lymphoblastic leukemia and was filed ... Center, where Phase 1 clinical trials are currently ... important news for patients who may benefit from ...
Breaking Medicine Technology:Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 2Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 3
(Date:11/26/2014)... 26, 2014 Senior Planning Services, providing ... a nonprofit organization providing the adult demographic education ... help seniors navigate the rough seas of applying for ... seniors on the topic of Medicaid eligibility and proper ... process of applying for this coverage. , Senior ...
(Date:11/26/2014)... November 26, 2014 ISI Telemanagement ... solutions, has been award the 2014 Lync ... This award comes as a great honor to ... the Lync ecosystem. Specifically, ISI offers an integrated ... of Lync communication, including voice, video, Lync IM, ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 Call 866-997-4948 ... requirements or email the details on sales(at)researchmoz(dot)us , ... and drug discovery market 2014" with deep study of ... the result of high blood sugar. The global glucose ... linked to the growing number of diabetics in the ...
(Date:11/26/2014)... November 26, 2014 Bunion Bootie, the ... prices in an early celebration of the early holiday ... being offered at the promotional price of $29.95 each ... in addition to any automatic discounts applied when buying ... Bootie website for complete details. It’s simple: purchasing ...
(Date:11/26/2014)... Louisiana (PRWEB) November 26, 2014 ... pain relief and specialists in minimally invasive spine ... Samer Shamieh into the rapidly growing provider network ... The addition coincides with the network’s continuing ... medical treatment for Louisiana residents who are suffering ...
Breaking Medicine News(10 mins):Health News:Senior Planning Services Teams Up with SeniorNet To Educate Seniors On Medicaid Planning 2Health News:ISI Telemanagement Solutions, Inc. has been Awarded the 2014 Microsoft Lync Pioneer Award 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 3Health News:Bunion Bootie Temporarily Lowering Prices for Holiday Shopping, Starting Today! 2Health News:Louisiana Back Institute Welcomes Dr. K. Samer Shamieh into Medical Provider Network 2
... NORTH HOLLYWOOD, Calif., June 17 IPC The,Hospitalist Company, ... group practice, today announced that it continues to experience,favorable ... net,revenues to be in the range of $57 million ... range of $4.2 million to $4.6 million. Absent the,impact ...
... CEO Scott Kornhauser,announced the appointment of Bryan Hebert ... Hebert was a former consulting partner with,over 18 ... in the healthcare,industry., Mr. Hebert,s responsibilities will ... market share for Healthation. Prior to,joining Healthation, Mr. ...
... Men whose tumors recur after prostate cancer surgery are ... term if they undergo radiotherapy within two years of ... whose new tumors were growing fastest, according to results ... Hopkins Medical Institutions researchers reported June 18 in the ...
... in DNA, study finds, , , TUESDAY, June 17 (HealthDay ... when it comes to cancer risk, according to a ... research suggests that stringent dietary changes, getting more exercise ... hundreds of genes. Some of the changes positively ...
... HILL, N.C., June 17 Across industry sectors,sales ... common operational, strategic and time management practices,according to ... LLC., The study shows the client still ... spend 21 percent of their time,building solutions for ...
... the death rate and might need to be used ... News) -- Countering common medical theory, a new study ... many men whose prostate cancer recurs aggressively after surgery. ... that recurs after surgery seem to benefit from salvage ...
Cached Medicine News:Health News:IPC The Hospitalist Company, Inc. Provides Second Quarter 2008 Outlook 2Health News:IPC The Hospitalist Company, Inc. Provides Second Quarter 2008 Outlook 3Health News:IPC The Hospitalist Company, Inc. Provides Second Quarter 2008 Outlook 4Health News:Radiation therapy prolongs life in men with recurrent prostate cancer 2Health News:Lifestyle Changes Affect Cancer Genes 2Health News:Lifestyle Changes Affect Cancer Genes 3Health News:High-Performing Sales Forces Share Key Practices to Achieve Optimal Performance 2Health News:Radiation May Help When Prostate Cancer Returns 2Health News:Radiation May Help When Prostate Cancer Returns 3
Intended for the quantitative determination of gammaglutamyl transferase activity in serum or plasma. Single vial, dry powder reagent. Readily soluble at room temperature. Reaction: Kinetic. Waveleng...
Intended for the quantitative determination of calcium in serum. Endpoint Reaction. Reaction complete within one minute, color developed is stable for 30 minutes. Wavelength: 570 nm. Linearity: 16 mg...
For the quantitative determination of alanine aminotransferase in serum used in routine examination and monitoring of therapy and relapses....
For the quantitative determination of Alanine Aminotransferase in serum. Optimized IFCC without P-5'-P, Linearity: 500 IU/L at 37 C. Liquid Working Reagent prepared with simple 1:9 dilution....
Medicine Products: